0001213900-21-036889 | 10-Q | XBRL Viewer | Oramed Pharmaceuticals INC

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	May 31, 2021	Jul. 14, 2021
Document Information Line Items
Entity Registrant Name	ORAMED PHARMACEUTICALS INC.
Document Type	10-Q
Current Fiscal Year End Date	--08-31
Entity Common Stock, Shares Outstanding		32,514,145
Amendment Flag	false
Entity Central Index Key	0001176309
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	May 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Incorporation, State or Country Code	DE
Document Transition Report	false
Entity File Number	000-50298
Entity Interactive Data Current	Yes

Leases (Details) - Schedule of operating right-of-use assets and operating lease liabilities $ in Thousands	May 31, 2021 USD ($)
Schedule of operating right-of-use assets and operating lease liabilities [Abstract]
Operating right-of-use assets	$ 560
Operating lease liabilities, current	129
Operating lease liabilities long-term	431
Total operating lease liabilities	$ 560

Label	Element	Value
GrantsFromEuropeanCommissionDescription	ormp_GrantsFromEuropeanCommissionDescription	During fiscal year 2020, the Company received an aggregate payment of €50,000 from the EC under The European Innovation Council Accelerator (previously known as SME Instrument) of the European Innovation Programme Horizon 2020.
DescriptionOfMilestonePayment	ormp_DescriptionOfMilestonePayment	the initial payment of $3,000 was received in January 2016. Following the achievement of certain milestones, the second and third payments of $6,500 and $4,000, respectively, were received in July 2016, the fourth milestone payment of $4,000 was received in October 2016 and the fifth milestone payment of $3,000 was received in January 2019.
DescriptionOfMilestonePayment	ormp_DescriptionOfMilestonePayment	On August 21, 2020, the Company received a letter from HTIT, disputing certain pending payment obligations of HTIT under the TLA. The payment obligation being disputed is $6,000, out of which only an amount of $2,000 has been received and has been included in Deferred revenues in each of the consolidated balance sheets as of May 31, 2021 and for the fiscal years ended August 31, 2020, and 2019. The Company wholly disputes the claims made by HTIT and has been engaged in discussions and exchanges with HTIT in an attempt to clarify and resolve disagreements between the parties regarding milestone payments and work plan implementation.
IPRD	ormp_IPRD	$ 1,040,000
IPRD	ormp_IPRD
AmortizedCosts	ormp_AmortizedCosts	5,930,000
AmortizedCosts	ormp_AmortizedCosts	126,000
AmortizedCosts	ormp_AmortizedCosts	7,288,000
AmortizedCosts	ormp_AmortizedCosts	13,344,000
AmortizedCosts	ormp_AmortizedCosts	5,295,000
AmortizedCosts	ormp_AmortizedCosts	74,000
AmortizedCosts	ormp_AmortizedCosts	3,928,000
AmortizedCosts	ormp_AmortizedCosts	9,297,000
AggregateOfferingPrice	ormp_AggregateOfferingPrice	15,000,000
AggregateOfferingPrice	ormp_AggregateOfferingPrice	40,000,000
AvailableForSaleSecuritiesGrossUnrealizedGainLoss	ormp_AvailableForSaleSecuritiesGrossUnrealizedGainLoss	(91,000)
AvailableForSaleSecuritiesGrossUnrealizedGainLoss	ormp_AvailableForSaleSecuritiesGrossUnrealizedGainLoss
AvailableForSaleSecuritiesGrossUnrealizedGainLoss	ormp_AvailableForSaleSecuritiesGrossUnrealizedGainLoss	626,000
AvailableForSaleSecuritiesGrossUnrealizedGainLoss	ormp_AvailableForSaleSecuritiesGrossUnrealizedGainLoss	535,000
AvailableForSaleSecuritiesGrossUnrealizedGainLoss	ormp_AvailableForSaleSecuritiesGrossUnrealizedGainLoss	(29,000)
AvailableForSaleSecuritiesGrossUnrealizedGainLoss	ormp_AvailableForSaleSecuritiesGrossUnrealizedGainLoss
AvailableForSaleSecuritiesGrossUnrealizedGainLoss	ormp_AvailableForSaleSecuritiesGrossUnrealizedGainLoss	56,000
AvailableForSaleSecuritiesGrossUnrealizedGainLoss	ormp_AvailableForSaleSecuritiesGrossUnrealizedGainLoss	27,000
PrepaidPensionCost	ormp_PrepaidPensionCost	20,000
PrepaidPensionCost	ormp_PrepaidPensionCost	18,000
FINANCIALINCOMEEXPENSESNET	ormp_FINANCIALINCOMEEXPENSESNET	(1,010,000)
FINANCIALINCOMEEXPENSESNET	ormp_FINANCIALINCOMEEXPENSESNET	(225,000)
FINANCIALINCOMEEXPENSESNET	ormp_FINANCIALINCOMEEXPENSESNET	(493,000)
FINANCIALINCOMEEXPENSESNET	ormp_FINANCIALINCOMEEXPENSESNET	10,000
PaymentsToAcquireFundsInRespectOfEmployeeRightsUponRetirement	ormp_PaymentsToAcquireFundsInRespectOfEmployeeRightsUponRetirement	1,000
PaymentsToAcquireFundsInRespectOfEmployeeRightsUponRetirement	ormp_PaymentsToAcquireFundsInRespectOfEmployeeRightsUponRetirement	$ 1,000
ConsultingAgreementsDescription	ormp_ConsultingAgreementsDescription	The Consulting Agreements are both terminable by either party upon 140 days prior written notice. The Consulting Agreements, as amended, provide that KNRY will be reimbursed for reasonable expenses incurred in connection with the performance of the Consulting Agreements and that the monthly consulting fee paid to the CEO and the CSO is NIS 127,570 ($39) and NIS 92,522 ($28), respectively.
PurchaseOfMutualFunds	ormp_PurchaseOfMutualFunds
PurchaseOfMutualFunds	ormp_PurchaseOfMutualFunds	3,211,000
Receivable	ormp_Receivable	1,500,000
Receivable	ormp_Receivable
LongTermPurchaseCommitmentBonusAmount	ormp_LongTermPurchaseCommitmentBonusAmount	2,905,000
LicenseCostsPayable	ormp_LicenseCostsPayable	$ 3,000,000
RoyaltyTerm	ormp_RoyaltyTerm	15 years
AggregateNetProceeds	ormp_AggregateNetProceeds	$ 10,987,000
AdditionalPaidInCapitals	ormp_AdditionalPaidInCapitals	(1,045,000)
AdditionalPaidInCapitals	ormp_AdditionalPaidInCapitals
ShortTermInvestmentPreferredEquity	ormp_ShortTermInvestmentPreferredEquity
ShortTermInvestmentPreferredEquity	ormp_ShortTermInvestmentPreferredEquity	481,000
ChangesAtFairValueOfInvestments	ormp_ChangesAtFairValueOfInvestments	759,000
ChangesAtFairValueOfInvestments	ormp_ChangesAtFairValueOfInvestments	(323,000)
PaymentsToAcquireMutualFunds	ormp_PaymentsToAcquireMutualFunds	(3,779,000)
PaymentsToAcquireMutualFunds	ormp_PaymentsToAcquireMutualFunds
NonRefundableFees	ormp_NonRefundableFees	500,000
IncreaseDecreaseInLiabilityForEmployeeRightsUponRetirement	ormp_IncreaseDecreaseInLiabilityForEmployeeRightsUponRetirement	2,000
IncreaseDecreaseInLiabilityForEmployeeRightsUponRetirement	ormp_IncreaseDecreaseInLiabilityForEmployeeRightsUponRetirement	(5,000)
OperatingLeaseAsset	ormp_OperatingLeaseAsset	$ 168,000
SharebasedCompensationsArrangementBySharebasedPaymentAwardPlanModificationDescriptionAndTerms	ormp_SharebasedCompensationsArrangementBySharebasedPaymentAwardPlanModificationDescriptionAndTerms	the Company entered into an underwriting agreement (the “Agreement”) with National Securities Corporation (the “Underwriter”), in connection with a public offering (the “Offering”) of 5,250,000 shares of the Company’s common stock, at an offering price of $4.00 per share. Under the terms of the Agreement, the Company granted the Underwriter a 45-day option to purchase from the Company up to an additional 787,500 shares of common stock at the public offering price (the “Over-Allotment Option”). In connection with the Offering, the Company also agreed to issue to the Underwriter, or its designees, warrants (the “Underwriter’s Warrants”), to purchase up to an aggregate of 7% of the shares of common stock sold in the Offering (including any additional shares sold during the 45-day option period), at an exercise price of $4.80 per share. The Underwriter’s Warrants issued in the Offering will be exercisable at any time and from time to time, in whole or in part, commencing nine months from issuance for a period of three years from the date of issuance. The closing of the sale of the Offering occurred on March 2, 2020. On April 9, 2020, the Company issued 180,561 shares of Common Stock and 12,640 Underwriter’s Warrants pursuant to a partial exercise by the Underwriter of the Over-Allotment Option (the “Partial Over-Allotment Option Exercise”). The net proceeds to the Company from the Offering, including from the Partial Over-Allotment Option Exercise, after deducting the underwriting discount and the Company’s estimated Offering expenses were $19,894.
AssetAcquisitionDescription	ormp_AssetAcquisitionDescription	the Company entered into the Oravax License Agreement and into the Stockholders Agreement with Oravax. On that date, Oravax’s assets were (1) in process research and development of COVID-19 vaccine technology; and (2) $1,500 to be received in cash (at the date of transaction it was recorded as a note receivable; the amount was paid in July 2021). According to the Stockholders Agreement, Oravax issued 1,890,000 shares of its capital stock to the Company, representing 63% of the issued and outstanding share capital of Oravax, on a fully diluted basis, as of the date of issuance.
ProceedsFromIssuanceOfCommonStockAndWarrants	ormp_ProceedsFromIssuanceOfCommonStockAndWarrants	$ 41,127,000
ProceedsFromIssuanceOfCommonStockAndWarrants	ormp_ProceedsFromIssuanceOfCommonStockAndWarrants	22,295,000
InterestReceived	ormp_InterestReceived	404,000
InterestReceived	ormp_InterestReceived	710,000
AgreementPayment	ormp_AgreementPayment	8,000,000
AggregateAmount	ormp_AggregateAmount	$ 1,500,000
LicenseAgreementDescription	ormp_LicenseAgreementDescription	the Company has recognized revenue associated with this agreement in the aggregate amount of $14,754, of which $681 was recognized in the quarter ended May 31, 2021, and deferred the remaining amount of $7,628 which is presented as deferred revenues on the condensed consolidated balance sheet.
OperatingLeasesLiabilities	ormp_OperatingLeasesLiabilities	$ 168,000
ProceedsFromStockOptionsAndWarrantsExercised	ormp_ProceedsFromStockOptionsAndWarrantsExercised	6,742,000
ProceedsFromStockOptionsAndWarrantsExercised	ormp_ProceedsFromStockOptionsAndWarrantsExercised	13,000
CostOfAssets	ormp_CostOfAssets	1,500,000
AggregateOferingPrice	ormp_AggregateOferingPrice	$ 28,000,000
RoyalitiesAgreementDescription	ormp_RoyalitiesAgreementDescription	(i) royalties equal to 7.5% on net sales, as defined in the Oravax License Agreement, of each product commercialized by Oravax, its affiliates and permitted sublicensees related to the License during the term specified in the Oravax License Agreement, (ii) sublicensing fees equal to 15% of any non-sales-based consideration received by Oravax from a permitted sublicensee and (iii) other payments ranging between $25,000 to $100,000, based on certain sales milestones being achieved by Oravax.

Print Document View Excel Document
Cover Document And Entity Information Notes Details Leases (Details) - Schedule of operating right-of-use assets and operating lease liabilities Uncategorized Uncategorized Items - ormp-20210531.xml All Reports